Genmab and Seagen Announce That TIVDAK (tisotumab vedotin-tftv) Met its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic...
COPENHAGEN, Denmark & BOTHELL, Wash.--(BUSINESS WIRE)--Sep 4, 2023--
COPENHAGEN, Denmark & BOTHELL, Wash.--(BUSINESS WIRE)--Sep 4, 2023--